News & Events
Press Releases, Publications & Events
2024
FEB – We’re excited to announce our collaboration with University of Alaska Fairbanks to study Canine Cognitive Disorder (CCD) in older working and companion dogs in Alaska. “Like in humans with Alzheimer’s disease, CCD can have a terrible toll on older dogs.” –@Judy Kelleher-Andersson MORE
2023
AUG – Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease MORE
AUG – Longevity Technology News Recognizes Significant Advancement of NNI-362 for the Treatment of Alzheimer’s Disease MORE
JUN – Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362 MORE
MAY – Neuronascent’s CEO will present “Therapy-Induced Neuron Genesis Reverses Developmental Delay-FXS” at the World Orphan Drug Congress 2023
APR – Neuronascent Announces the Expansion of its Board of Directors MORE
2022
NOV – Neuronascent to Present Further NNI-362 Phase1a Data at CTAD 2022 for Alzheimer’s Disease MORE
JUN – Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome MORE
MAY – Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome MORE
APR – NeuroNascent Continues to See Positive Clinical Data with Alzheimer’s Therapy MORE
APR – NNI-362 Is Safe, Lowers Alzheimer’s Biomarker in Older, Healthy Adults MORE
MAR – Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease MORE
2021
NOV – Dr Judith Kelleher-Andersson, NeuroNascent President & CEO, was interviewed by Catherine Shaffer of Genetic Engineering & Biotechnology News (GEN). Dr Kelleher-Andersson’s comments are included in the November 2021 issue of Genetic Engineering & Biotechnology News (NeuroNascent genengnews.com), under the topic “Stimulating Neurogenesis.” This interview was a follow-up to the Fourth Annual Neuropsychiatric Drug Development Summit, a virtual event that was held September 28–30, 2021. MORE
NOV – NeuroNascent Presents Results of Phase 1a Human Safety Clinical Trial of NNI-362 at the CTAD conference in Boston, November 9-12. MORE
SEP – Neuronascent Releases Positive Topline Phase 1a Safety Results of NNI-362 for Alzheimer’s Disease. MORE
MAR – Longevity Technology publishes “Reversing neurodegeneration with new neurons and clinical trials,” an article on NeuroNascent’s clinical-stage drug, NNI-362, and its potential to reverse neurodegenerative diseases such as Alzheimer’s and Parkinson’s. MORE
MAR – The recent publication of the pre-clinical results of Alzheimer’s disease clinical candidate, NNI-362, in SCR&T was noted by the Alzheimer’s Association Business Consortium. MORE
JAN – Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal. MORE
JAN – Stem Cell Research & Therapy Publishes “Novel Pharmacotherapy: NNI-362, an Allosteric p70S6 Kinase Stimulator, Reverses Cognitive and Neural Regenerative Deficits in Models of Aging and Disease.” MORE
2020
JUL – Judith Kelleher-Andersson, CEO of Neuronascent is pleased to be a presenter at the NIA-AA Symposium: Enabling Precision Medicine for AD through Open Science, on July 30th, 2020 at this year’s Virtual AAIC 2020 conference. The title of Judith’s invited talk for this symposium is “Neuron regenerative therapy, NNI-362, aiming to reverse deficits in AD, and AD in down syndrome.”
JUL – AngelMD Startup Spotlight: NeuroNascent. “NeuroNascent is taking a novel approach to solving age-related neurodegenerative disease, including Alzheimer’s. The team behind the company is both creative and seasoned, which shows in their answers during the interview.” MORE
MAY – Father of the founder of Neuronascent – an age-related therapeutics company – turns 100! MORE
JAN – CEO and Founder of Neuronascent, Dr. Kelleher-Andersson, was invited to present at the UC Davis MIND Institute. Her seminar is on Fragile X syndrome. MORE
2019
SEP – In biotechPrimer, Emily Burke, PhD, highlights the uniqueness and potential of NNI-362 for “Reviving the Brain?” in Alzheimer’s disease patients. MORE
MAY – Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer’s Disease MORE
2018
NOV – Neuronascent’s CEO/Founder invited to present on an aging and regeneration panel at the 2018 World Alliance Forum -San Francisco.
Her presentation was titled, “Developing Novel Therapies that Regenerate Neurons within Aging Brain.” MORE
SEP – Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease MORE
2017
NOV – Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology MORE
OCT – Opened Fundable Project MORE
APR – Neuronascent Appoints New Board Member. MORE
JAN – Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders. MORE
2016
FEB – Neuronascent’s Research Tool Aimed at Stroke Tolerance is Characterized in 2016 Publication. The title of the article is “Arctic ground squirrel neuronal progenitor cells resist oxygen and glucose deprivation-induced death,” authored by the Founder and colleagues. MORE
2015
APR – Neuronascent Secures Financing for Development of Its Alzheimer’s Therapeutic. MORE
FEB – Neuronascent Announces Expanded Patent Coverage In US and Russia For Its Alzheimer’s Disease and Down Syndrome Therapeutics. MORE
2014
SEP – NI Research’s September 2014 Issue of NeuroPerspective fully reviews Alzheimer’s therapeutics and prominently mentions Neuronascent, Inc. In covering the different approaches to Alzheimer’s therapeutic development, the review notes that “The one neurogenesis-focused company prioritizing Alzheimer’s is Neuronascent”. NeuroPerspective publisher Dr. Harry Tracy also called Neuronascent “the neurogenesis specialist,” and he selected Neuronascent’s program as one of the ‘Top Ten’ CNS partnering opportunities to be presented at the Informa Therapeutic Area Partnerships conference, which will be held in Boston this November.
APR – Neuronascent Successfully Completes Pre-IND Meeting with FDA for Alzheimer’s Disease Therapeutic. MORE
MAR – Neuronascent to participate in the Redefining Early Stage Investment (RESI) Innovation Challenge, an investment meeting in Boston, MA, March 24, 2014.
JAN – Neuronascent, Inc. Announces Issuance of US Patent Covering Second-Generation Neurorestorative Therapeutic Candidate. MORE
2013
NOV – Neuronascent, Inc. Alzheimer’s Disease Therapeutic Candidate Selected for Preclinical Safety Testing. MORE
2012
SEP – NeuroNascent Aims to Reverse Neurodegenerative Damage. Full BioWorld Today article available
MAY – Dr. Kelleher-Andersson, the President and CSO of Neuronascent, Inc. presented at the annual Neurotechnology Industry Organization meeting in Boston. Kelleher-Andersson led off the Frontiers in Neurotech panel, by describing the large unmet need for disease modifying therapies to treat Alzheimer’s disease, post-traumatic stress disorder and Down syndrome, then suggested how Neuronascent’s first-in-class therapeutic candidates might address those unmet needs.
MAR – Patent claims were issued in South Korea for Neuronascent’s National patent application entitled “Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration”. Patent claims had previously been issued in the US and Russia back in 2011.
FEB – The founder and President of Neuronascent, Inc., Dr. Judith Kelleher-Andersson presented details of Neuronascent’s Alzheimer’s disease and Down syndrome pre-clinical therapeutic candidates at the 14th American Society for Experimental Neurotherapeutics conference in Washington, DC.